A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma
The purpose of this trial is to find out the maximum tolerated dose (MTD) of bortezomib (VELCADE) in combination with pralatrexate in patients with previously treated multiple myeloma, AL amyloid and Waldenstroem's macroglobulinemia.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Pralatrexate
- drug : velcade
Phase: Phase 1
Ages Eligible For Study:
- The patient has relapsed or refractory multiple myeloma that has progressed following at least on prior therapy. - Relapsed myeloma is defined in patients as at least 25% increasing monoclonal (M)-protein in serum or urine or in the size of a plasmacytoma compared to a best response reached after previous therapy. - Refractory myeloma is defined as failure to achieve at least a minor response (patient achieved stable disease as his/her best response) or progression of disease on current therapy or within 60 days of last dose of current therapy. - The patient has measurable disease defined as one of the following: 1. serum M-protein >=1 g/dL 2. urine M-protein >=200 mg/24 hours - Must have received at least one (1) prior line of systemic treatment that may have included VELCADE. a. NOTE: Patients may have undergone prior allogeneic or autologous stem cell transplantation (stem cell transplant with high dose induction chemotherapy with/without planned maintenance therapy will be considered one line of therapy). - No cytotoxic chemotherapy within 4 weeks prior to registration for protocol therapy. a. NOTE: this interval may be reduced to 14 days for thalidomide, lenalidomide, VELCADE or corticosteroids, provided other entry criteria are met. - No concurrent steroid use in doses greater than 10 mg daily of Prednisone (or equivalent) if given for management of co-morbid conditions. - Age >= 18 at the time of consent. - The patient has a life expectancy of more than 3 months. - No known central nervous system involvement by myeloma. - ECOG performance status 0-2. - No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, or psychiatric illness that in the opinion of the investigator would limit compliance with study requirements. - Patients must have adequate bone marrow function: Platelets >100 x 109/L, Hemoglobin > 8.0g/dL and ANC > 1 x 109/L - Patients must have adequate liver functions: AST and ALT < 2.5 X upper limit of normal, Total bilirubin <= 1.5 x ULN - Patients must have adequate renal function defined as creatinine clearance of 30 ml/minute (Cockcroft-Gault). - The patient must have been on a regimen of 1.0 - 1.25 mg PO QD of folic acid for at least 10 days prior to the planned start of pralatrexate and received 1 mg IM of vitamin B12 within 10 weeks of the planned start of pralatrexate. - Patients with reproductive potential must use an effective method of contraception to avoid pregnancy for the duration of the trial. - If female of childbearing potential, pregnancy test must be negative within 7 days prior to registration for protocol therapy. - Ability to understand and the willingness to sign a written informed consent document including HIPAA authorization for release of personal health information. - The patient must be willing and able to receive outpatient treatment and laboratory monitoring at the Stanford Cancer Center.